BACKGROUND: The study objectives were: 1) to report on invasive aspergillosis patients in a hematology department; and 2) to estimate its incidence according to the hematologic diagnosis. DESIGN AND METHODS: A prospective survey of invasive aspergillosis cases was undertaken between January 2004 and December 2009 in the hematology department of a university hospital. Meetings with clinicians, mycologists and infection control practitioners were organized monthly to confirm suspected aspergillosis cases. Demographic characteristics, clinical and complementary examination results were recorded prospectively. Information on hospitalization was extracted from administrative databases. Invasive aspergillosis diagnosis followed the European Organization for Research and Treatment of Cancer criteria, and proven and probable IA cases were retained. A descriptive analysis was conducted with temporal trends of invasive aspergillosis incidence assessed by adjusted Poisson regression. RESULTS: Overall, 4,073 hospitalized patients (78,360 patient-days) were included in the study. In total, 127 (3.1%) patients presented invasive aspergillosis. The overall incidence was 1.6 per 1,000 patient-days (95% confidence interval: 1.4, 1.9) with a decrease of 16% per year (-1%, -28%). The incidence was 1.9 per 1,000 patient-days (1.5, 2.3) in acute myeloid leukemia patients with a decrease of 20% per year (-6%, -36%). Serum Aspergillus antigen was detected in 89 (71%) patients; 29 (23%) had positive cultures, and 118 (93%), abnormal lung CT scans. One-month mortality was 13%; 3-month mortality was 42%. Mortality tended to decrease between 2004 and 2009. CONCLUSIONS: Invasive aspergillosis incidence and mortality declined between 2004 and 2009. Knowledge of invasive aspergillosis characteristics and its clinical course should help to improve the management of these patients with severe disease.
BACKGROUND: The study objectives were: 1) to report on invasive aspergillosispatients in a hematology department; and 2) to estimate its incidence according to the hematologic diagnosis. DESIGN AND METHODS: A prospective survey of invasive aspergillosis cases was undertaken between January 2004 and December 2009 in the hematology department of a university hospital. Meetings with clinicians, mycologists and infection control practitioners were organized monthly to confirm suspected aspergillosis cases. Demographic characteristics, clinical and complementary examination results were recorded prospectively. Information on hospitalization was extracted from administrative databases. Invasive aspergillosis diagnosis followed the European Organization for Research and Treatment of Cancer criteria, and proven and probable IA cases were retained. A descriptive analysis was conducted with temporal trends of invasive aspergillosis incidence assessed by adjusted Poisson regression. RESULTS: Overall, 4,073 hospitalized patients (78,360 patient-days) were included in the study. In total, 127 (3.1%) patients presented invasive aspergillosis. The overall incidence was 1.6 per 1,000 patient-days (95% confidence interval: 1.4, 1.9) with a decrease of 16% per year (-1%, -28%). The incidence was 1.9 per 1,000 patient-days (1.5, 2.3) in acute myeloid leukemiapatients with a decrease of 20% per year (-6%, -36%). Serum Aspergillus antigen was detected in 89 (71%) patients; 29 (23%) had positive cultures, and 118 (93%), abnormal lung CT scans. One-month mortality was 13%; 3-month mortality was 42%. Mortality tended to decrease between 2004 and 2009. CONCLUSIONS:Invasive aspergillosis incidence and mortality declined between 2004 and 2009. Knowledge of invasive aspergillosis characteristics and its clinical course should help to improve the management of these patients with severe disease.
Authors: W B Grow; J S Moreb; D Roque; K Manion; H Leather; V Reddy; S A Khan; K J Finiewicz; H Nguyen; C J Clancy; P S Mehta; J R Wingard Journal: Bone Marrow Transplant Date: 2002-01 Impact factor: 5.483
Authors: D A Stevens; V L Kan; M A Judson; V A Morrison; S Dummer; D W Denning; J E Bennett; T J Walsh; T F Patterson; G A Pankey Journal: Clin Infect Dis Date: 2000-04-20 Impact factor: 9.079
Authors: Wouter Meersseman; Stefaan J Vandecasteele; Alexander Wilmer; Eric Verbeken; Willy E Peetermans; Eric Van Wijngaerden Journal: Am J Respir Crit Care Med Date: 2004-06-30 Impact factor: 21.405
Authors: Michelle R Ananda-Rajah; Christoph Bergmeir; François Petitjean; Monica A Slavin; Karin A Thursky; Geoffrey I Webb Journal: JCO Clin Cancer Inform Date: 2017-11
Authors: Yuqian Sun; He Huang; Jing Chen; Jianyong Li; Jun Ma; Juan Li; Yingmin Liang; Jianmin Wang; Yan Li; Kang Yu; Jianda Hu; Jie Jin; Chun Wang; Depei Wu; Yang Xiao; Xiaojun Huang Journal: Tumour Biol Date: 2014-10-08
Authors: Sapha Barkati; Simon F Dufresne; Sylvie Bélanger; Barbara Vadnais; Julie Bergeron; Annie Claude Labbé; Michel Laverdière Journal: CMAJ Open Date: 2014-05-07